To keep sales force busy, Lilly takes on new drug

Back to TopCommentsE-mailPrintBookmark and Share

Eli Lilly and Co. beefed up its sales force this summer to promote its new blood thinner Effient. But it decided it needed to put at least one more arrow in their quivers.

Indianapolis-based Lilly has agreed to have its U.S. sales personnel promote a new cholesterol-fighting drug developed by Japan-based Kowa Pharamceuticals Ltd., called Livalo.

Financial terms of the deal were not specified. But Lilly will pay Kowa an upfront fee, help shoulder the marketing costs, and then in return receive co-promotion fees that escalate as the drug’s sales go up. Lilly will also license the drug to sell in Latin American countries.

"Our co-promotion arrangement in the U.S. and licensing arrangement in Latin America will allow Lilly to expand our product offerings in the cardiovascular therapeutic area and more efficiently utilize our existing cardiovascular sales force,” said Lilly CEO John Lechleiter, in a statement.

Lilly has only two major products aimed specifically at heart patients: Effient and ReoPro, a drug used for patients undergoing angioplasty or stent procedures, which hit the market in 1995. Both have modest sales, although Effient is expected to eventually achieve annual sales topping $1 billion.

Livalo, approved in the U.S. in August, is a late arrival to a huge party. Cholesterol-fighting drugs, called statins, were the second-best-selling class of drugs in the U.S. last year, with total retail sales of $14.5 billion, according to market research firm IMS Health.

Total dollars in the market have been declining, however, as cheaper generic versions of statins have hit the market the past three years. When the statin Lipitor, the best-selling drug in the world, loses its patent protection in June 2011, price competition will be fierce for Livalo.

But Kowa officials say Livalo appears to help some patients for whom existing statins do not. Also, they emphasize, Livalo has lower chances of negative interactions with other drugs, including clot-busting drug Warfarin.


Post a comment to this story

We reserve the right to remove any post that we feel is obscene, profane, vulgar, racist, sexually explicit, abusive, or hateful.
You are legally responsible for what you post and your anonymity is not guaranteed.
Posts that insult, defame, threaten, harass or abuse other readers or people mentioned in IBJ editorial content are also subject to removal. Please respect the privacy of individuals and refrain from posting personal information.
No solicitations, spamming or advertisements are allowed. Readers may post links to other informational websites that are relevant to the topic at hand, but please do not link to objectionable material.
We may remove messages that are unrelated to the topic, encourage illegal activity, use all capital letters or are unreadable.

Messages that are flagged by readers as objectionable will be reviewed and may or may not be removed. Please do not flag a post simply because you disagree with it.

Sponsored by

facebook - twitter on Facebook & Twitter

Follow on TwitterFollow IBJ on Facebook:
Follow on TwitterFollow IBJ's Tweets on these topics:
Subscribe to IBJ
  1. How much you wanna bet, that 70% of the jobs created there (after construction) are minimum wage? And Harvey is correct, the vast majority of residents in this project will drive to their jobs, and to think otherwise, is like Harvey says, a pipe dream. Someone working at a restaurant or retail store will not be able to afford living there. What ever happened to people who wanted to build buildings, paying for it themselves? Not a fan of these tax deals.

  2. Uh, no GeorgeP. The project is supposed to bring on 1,000 jobs and those people along with the people that will be living in the new residential will be driving to their jobs. The walkable stuff is a pipe dream. Besides, walkable is defined as having all daily necessities within 1/2 mile. That's not the case here. Never will be.

  3. Brad is on to something there. The merger of the Formula E and IndyCar Series would give IndyCar access to International markets and Formula E access the Indianapolis 500, not to mention some other events in the USA. Maybe after 2016 but before the new Dallara is rolled out for 2018. This give IndyCar two more seasons to run the DW12 and Formula E to get charged up, pun intended. Then shock the racing world, pun intended, but making the 101st Indianapolis 500 a stellar, groundbreaking event: The first all-electric Indy 500, and use that platform to promote the future of the sport.

  4. No, HarveyF, the exact opposite. Greater density and closeness to retail and everyday necessities reduces traffic. When one has to drive miles for necessities, all those cars are on the roads for many miles. When reasonable density is built, low rise in this case, in the middle of a thriving retail area, one has to drive far less, actually reducing the number of cars on the road.

  5. The Indy Star announced today the appointment of a new Beverage Reporter! So instead of insightful reports on Indy pro sports and Indiana college teams, you now get to read stories about the 432nd new brewery open or some obscure Hoosier winery winning a county fair blue ribbon. Yep, that's the coverage we Star readers crave. Not.